These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3680584)

  • 1. Lorcainide for the treatment of refractory ventricular tachycardia: clinical and electrophysiologic results.
    Hanyok JJ; Kluger J; Chow MS; Fieldman A
    J Clin Pharmacol; 1987 Apr; 27(4):278-82. PubMed ID: 3680584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia.
    Somberg JC; Butler B; Flowers D; Tepper D; Maguire W; Willens H; Keren G; Miura D
    Am J Cardiol; 1984 Aug; 54(4):49B-54B. PubMed ID: 6465047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia.
    Somberg JC; Butler B; Flowers D; Keefe D; Torres V; Miura D
    Am J Cardiol; 1984 Aug; 54(4):43B-48B. PubMed ID: 6465046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term lorcainide therapy guided by electrophysiology studies.
    Somberg J; Butler B; Flowers D; Tepper D; Torres V
    Acta Cardiol; 1985; 40(6):621-36. PubMed ID: 3879419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term lorcainide therapy in patients with ventricular tachycardia.
    Somberg J; Butler B; Flowers D; Keefe D; Torres V; Miura D
    Am Heart J; 1985 Jan; 109(1):33-40. PubMed ID: 3966330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorcainide therapy for the high-risk patient post myocardial infarction.
    Somberg JC; Butler B; Torres V; Flowers D; Tepper D; Keefe D; Miura DS
    Am J Cardiol; 1984 Aug; 54(4):37B-42B. PubMed ID: 6465045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorcainide in patients with refractory ventricular tachyarrhythmia.
    Chesnie B; Lampert S; Podrid P; Lown B
    J Am Coll Cardiol; 1984 Jun; 3(6):1531-9. PubMed ID: 6715710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
    Echt DS; Mitchell LB; Kates RE; Winkle RA
    Circulation; 1983 Aug; 68(2):392-9. PubMed ID: 6861314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome.
    Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T
    Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical-electrophysiological study of the effect of lorcainide on induction of ventricular tachycardia (author's transl)].
    Breithardt G; Seipel L; Abendroth RR
    Z Kardiol; 1981 Jul; 70(7):530-5. PubMed ID: 7269732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and electrophysiologic effects of chronic lorcainide therapy in refractory ventricular tachycardia.
    Saksena S; Rothbart ST; Cappello G; Bernstein A; Somani P
    J Am Coll Cardiol; 1983 Sep; 2(3):538-44. PubMed ID: 6875117
    [No Abstract]   [Full Text] [Related]  

  • 12. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
    Platia EV; Estes M; Heine DL; Griffith LS; Garan H; Ruskin JN; Reid PR
    Am J Cardiol; 1985 Apr; 55(8):956-62. PubMed ID: 3984883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with oral lorcainide in patients with sustained ventricular tachycardia and fibrillation.
    Echt DS; Shapiro M; Trusso J; Mason JW; Winkle RA
    Am Heart J; 1985 Jan; 109(1):28-33. PubMed ID: 3966329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorcainide therapy in a cardiac arrest population.
    Somberg JC; Laux B; Wynn J; Keefe D; Miura DS
    Am Heart J; 1986 Apr; 111(4):648-53. PubMed ID: 3953387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intraventricular conduction.
    Stroobandt R; Kesteloot H
    Acta Cardiol; 1985; 40(6):637-48. PubMed ID: 3879420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic effect of lorcainide in patients taking digoxin.
    Giardina EG; Raby K; Saroff AL; Louie-Chu M
    J Clin Pharmacol; 1987; 27(5):378-83. PubMed ID: 3693581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological effects of lorcainide, a new antiarrhythmic drug. Observations in patients with and without pre-excitation.
    Bär FW; Farré J; Ross D; Vanagt EJ; Gorgels AP; Wellens HJ
    Br Heart J; 1981 Mar; 45(3):292-8. PubMed ID: 7470342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic effect of lorcainide during chronic treatment.
    Meinertz T; Kasper W; Kersting F; Bechtold H; Just H; Jähnchen E
    Arzneimittelforschung; 1980; 30(9):1593-5. PubMed ID: 7193031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.
    Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN
    Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial and long-term outpatient experience with lorcainide for suppression of malignant and potentially malignant ventricular arrhythmias.
    Anastasiou-Nana MI; Anderson JL; Hampton EM; Nanas JN; Lutz JR
    Am Heart J; 1985 Dec; 110(6):1168-75. PubMed ID: 4072873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.